Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.66 |
| ▸ | HTR3B | O95264 | 2/20 | 0.63 |
| ▸ | HTR3A | P46098 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5772609 | 1.00 | HRH4 (0.66) | HRH4HTR3BHTR3APOLBKMT2A | |
| SCHEMBL30223251 | 0.91 | HRH4 (0.73) | HRH4HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL405806 | 0.91 | HRH4 (0.73) | HRH4HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL405787 | 0.85 | HRH4 (0.60) | HRH4HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL6358386 | 0.85 | HRH4 (0.66) | HRH4HTR3BHTR3AKDM4E | |
| SCHEMBL404215 | 0.84 | HRH4 (0.61) | HRH4HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL406322 | 0.81 | HRH4 (0.67) | HRH4HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL27661218 | 0.81 | HRH4 (0.70) | HRH4HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL404202 | 0.81 | HRH4 (0.70) | HRH4HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL463021 | 0.80 | HRH4 (0.57) | HRH4HTR3BHTR3AKMT2AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-1670774-A1 | QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005033088-A1 | QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-14 | — | — | WO | disclosed |
| US-20050070527-A1 | For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070527-A1 | For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions | HRH4, HRH3, LTB4R | HRH4 1/4885HTR3B 134/4885HTR3A 225/4885 |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3B 113/4885HTR3A 153/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3B 113/4885HTR3A 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.